CAR T cells: Living HIV drugs. (26th July 2020)

• Record Type: Journal Article
• Authors: Namdari, Haideh; Rezaei, Farhad; Teymoori‐Rad, Majid; Mortezagholi, Sahar; Sadeghi, Ahmadreza; Akbari, Abolfazl
• Is Part Of: Reviews in medical virology. Volume 30:Number 6(2020)
• Page Start: 1
• Page End: 14
• Publication Date: 2020-07-26
• Subjects: CAR therapy -- HIV -- T cell; Medical virology -- Periodicals; Review Literature -- Periodicals; Virus Diseases -- Periodicals; Viruses -- Periodicals; 616.0194
• DOI: 10.1002/rmv.2139
• Languages: English
• ISSNs: 1052-9276

Abstract

Summary: Human immunodeficiency virus type 1 (HIV‐1), the virus that causes AIDS (acquired immunodeficiency syndrome), is a major global public health issue. Although the advent of combined antiretroviral therapy (ART) has made significant progress in inhibiting HIV replication in patients, HIV‐infected cells remain the principal cellular reservoir of HIV, this allows HIV to rebound immediately upon stopping ART, which is considered the major obstacle to curing HIV infection. Chimeric antigen receptor (CAR) cell therapy has provided new opportunities for HIV treatment. Engineering T cells or hematopoietic stem cells (HSCs) to generate CAR T cells is a rapidly growing approach to develop an efficient immune cell to fight HIV. Herein, we review preclinical and clinical data available for the development of CAR T cells. Further, the advantages and disadvantages of clinical application of anti‐HIV CAR T cells will be discussed.